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We thank Dr Lin for the letter to our article.
In our article,1 we gave the first systematic overview
of vascular access calcification and described risk
factors for the development of vascular access calcification
such as male gender, diabetes mellitus, and dialysis
vintage. Moreover, we found that the presence of vascular
access calcification is related to an increased mortality risk,
even after adjustment for these and other important
confounders. Therefore, the detection of vascular access
calcification represents a cost-effective and easy-to-
perform method to identify patients at increased
mortality risk.
As pointed out by Dr Lin, not only vascular access,
calcification, but also high-sensitive C-reactive protein,
carotid intima media thickness, and iliacal/femoral
calcification were related to increased mortality in our
study (Table 4 of original article1), and therefore could be
potential confounding factors on the predictive value of
vascular access calcification on mortality. In addition, we
performed a stepwise Cox regression analysis with the
above-mentioned potential confounders plus age (Table 1).
In this model we found that, even after adjustment of these
confounders, the presence of vascular access calcification
was associated with an approximately twofold mortality
risk (ranging from 1.77 to 2.60).
Taken together, the presence of vascular access calcifica-
tion is an important predictor of mortality in dialysis
patients.
1. Schlieper G, Kru¨ger T, Djuric Z et al. Vascular access calcification predicts
mortality in hemodialysis patients. Kidney Int 2008; 74: 1582–1587.
Georg Schlieper1, Diana C. Grootendorst2, Friedo W. Dekker2,
Nada Dimkovic3 and Juergen Floege1
1Nephrology and Clinical Immunology, RWTH University Hospital, Aachen,
Germany; 2Clinical Epidemiology, Leiden University Medical Center, Leiden,
The Netherlands and 3Center for Renal Diseases, Zvezdara University Medical
Center, Belgrade, Serbia
Correspondence: Georg Schlieper, Nephrology and Clinical Immunology,
RWTH University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany.
E-mail: gschlieper@ukaachen.de
Angiotensin-converting enzyme 2
(ACE2) gene and protein
expression in diabetic patients
without nephropathy
Kidney International (2009) 75, 1118–1119; doi:10.1038/ki.2009.50
To the Editor: Reich et al.1 investigated the angiotensin-
converting enzyme 2 (ACE2) gene and protein expression in
patients with diabetic nephropathy. The authors seem to
interchangeably use kidneys in patients with diabetes and
diabetic patients with kidney disease (i.e., diabetic nephro-
pathy), which are two different diagnoses. For example, ‘The
strengths of the current study are that we compared ACE2
and ACE expression in the kidney of subjects with type 2 DM
with the kidneys of healthy control subjectsy’1 seems to
conflict with the study by Tikellis et al.,2 which reported
ACE2 expression in rats with streptozocin-induced diabetes
after 24 weeks. The different glomerular expression of ACE2
in these two studies may not be a conflicting report but a
report of ACE2 expression in two separate cohorts. This
raises two questions: (1) Is there a difference in ACE2 gene
and protein expression between patients with diabetes
without nephropathy and diabetic patients with nephro-
pathy? and (2) is there a specific pattern of expression that
may predict future development of nephropathy in diabetic
patients without nephropathy?
Also, Parving et al.3 reported the antiproteinuric effect of
the renin inhibitor, aliskiren (in combination with Losartan)
in patients with diabetic nephropathy. As ACE2 activity is
dependent on production of angiotensin peptides from
angiotensin I and II, and angiotensin I is produced by the
action of renin on angiotensinogen, the use of renin
inhibitors will decrease production of angiotensin I as well
as angiotensin peptides 1–7 and 1–9. It would be interesting
to know what the long-term effect of rennin inhibitors will
be. The use of renin inhibitors may reduce or eliminate the
beneficial effect of the ACE2 pathway.
1. Reich HN, Oudit GY, Penninger JM et al. Decreased glomerular and
tubular expression of ACE2 in patients with type 2 diabetes and kidney
disease. Kidney Int 2008; 74: 1610–1616.
2. Tikellis C, Johnston CI, Forbes JM et al. Characterization of renal
angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension
2003; 41: 392–397.
Table 1 | Effect of vascular access calcification on total
mortality determined by stepwise Cox regression analysis
Model HR 95% CI P-value
Step 1 Vascular access calcification 2.14 1.11–4.12 0.023
Step 2 Step 1 + gender 2.29 1.15–4.55 0.018
Step 3 Step 2 + diabetes mellitus 2.24 1.12–4.49 0.023
Step 4 Step 3 + dialysis vintage 2.60 1.25–5.40 0.010
Step 4 + iliacal/femoral calcification 2.39 1.14–4.99 0.021
Step 4 + CRP 2.27 1.08–4.80 0.032
Step 4 + IMT 1.99 0.87–4.53 0.103
Step 5 Step 4 + age 2.53 1.24–5.15 0.010
Step 6 Step 5 + iliacal/femoral calcification 2.38 1.16–4.90 0.018
Step 7 Step 6 + CRP 2.02 0.94–4.34 0.070
Step 7 + IMT 1.77 0.77–4.05 0.180
CRP, high sensitive C-reactive protein (mg/l); 95% CI, 95% confidence interval; HR,
hazard ratio; IMT, carotid intima-media thickness (mm).
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3. Parving HH, Persson F, Lewis JB, et al., AVOID Study Investigators.
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
N Engl J Med 2008; 358: 2433–2446.
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We thank Dr Amao1 for the interest in our study of ACE2
expression in kidney biopsies of human subjects with
diabetic nephropathy (DN), and other forms of glomerular
disease.2 Indeed, we did not study ACE2 gene or protein
expression in biopsies of diabetic subjects without
DN and, as mentioned in our discussion, it is not known
whether the same observation would occur in such
individuals. The feasibility of this type of study is
questionable, given that it would be difficult to justify
kidney biopsy in human subjects without clinical evidence
of renal disease. Similarly, it is not known whether ACE2
expression in diabetic patients could be used to predict the
development of DN. We also agree that the reported
differences in ACE2 expression in different animal models
of DN and human studies could relate to disease stage.
Appreciation of the complexity of the renin–angiotensin
system and its intrinsic balances continues to grow. We
agree with Dr Amao that the potential influence of direct
renin inhibition on the protective effects of ACE2 merits
further study.
1. Amao OL. Angiotensin-converting enzyme 2 (ACE2) gene and protein
expression in diabetic patients without nephropathy. Kidney Int 2009; 75:
1118–1119.
2. Reich HN, Oudit GY, Penninger JM et al. Decreased glomerular and
tubular expression of ACE2 in patients with type 2 diabetes and kidney
disease. Kidney Int 2008; 74: 1610–1616.
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To the Editor: In a study comparing high-volume peritoneal
dialysis (HVPD) and daily hemodialysis (DHD), Gabriel
et al.1 report their experience from a randomized controlled
trial. The authors report a mortality of 58% for HVPD and
53% for DHD. Subsequently, the article mentions 24
survivors in HVPD and 29 survivors in DHD, each group
comprising 60 patients. Taking the figures of survivors into
account, the mortality for the HVPD group should have been
reported as 60% and that for the DHD group as 51.66% (or
as 52%, the nearest whole number).
The study also compares the efficacy of HVPD in
metabolic control with that of DHD. However, they excluded
patients with severe hypercatabolism according to Schrier’s
criteria2 at the time of randomization, giving the impression
that the authors accepted the limitations of HVPD before-
hand. Chitalia et al.3 have earlier reported peritoneal dialysis
to be reasonably effective in mild and moderate hyper-
catabolic acute renal failure. It would have been interesting to
observe the efficacy of HVPD in severely hypercatabolic
patients, especially when the authors have used very high
volumes of 36–44 l/day of dialysis fluid for 7 days a week with
a target Kt/V of 0.65/day.
1. Gabriel DP, Caramori JT, Martim LC et al. High volume peritoneal dialysis
vs daily hemodialysis: a randomized, controlled trial in patients with
acute kidney injury. Kidney Int 2008; 73(Suppl 108): S87–S93.
2. Schrier RW. Acute renal failure. Kidney Int 1979; 15: 205–216.
3. Chitalia V, Almeida AF, Rai H et al. Is peritoneal dialysis adequate for
hypercatabolic acute renal failure in developing countries? Kidney Int
2002; 61: 747–757.
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We appreciate the interest of Dr Palya and colleagues1 in
our paper.2 We agree that further exploration of the
relationship between progestin use, either with or without
estrogen, and loss of kidney function would be of great
interest. The importance of the type of progestin contained
in hormonal preparations has been previously high-
lighted.3,4 Studies have suggested a link between adverse
cardiac, vascular, and thrombotic events depending on the
type of progestin exposure,3,4 and indicate that the type of
progestin in a hormonal preparation may play a role in
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